179 related articles for article (PubMed ID: 35920658)
1. Passive Immunization with a Single Monoclonal Neutralizing Antibody Protects against Cutaneous and Mucosal Mouse Papillomavirus Infections.
Brendle SA; Li J; Cladel NM; Balogh KK; Booth J; Shearer DA; Walter V; Lu S; Christensen ND; Covington D; DeBroff J; Milici J; Zhu Y; Viscidi R; Hu J
J Virol; 2022 Aug; 96(16):e0070322. PubMed ID: 35920658
[TBL] [Abstract][Full Text] [Related]
2. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
[TBL] [Abstract][Full Text] [Related]
3. Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer.
Cladel NM; Budgeon LR; Balogh KK; Cooper TK; Brendle SA; Christensen ND; Schell TD; Hu J
Sci Rep; 2017 Dec; 7(1):16932. PubMed ID: 29208932
[TBL] [Abstract][Full Text] [Related]
4. Mouse papillomavirus infections spread to cutaneous sites with progression to malignancy.
Cladel NM; Budgeon LR; Cooper TK; Balogh KK; Christensen ND; Myers R; Majerciak V; Gotte D; Zheng ZM; Hu J
J Gen Virol; 2017 Oct; 98(10):2520-2529. PubMed ID: 28942760
[TBL] [Abstract][Full Text] [Related]
5. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
6. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.
Longet S; Schiller JT; Bobst M; Jichlinski P; Nardelli-Haefliger D
J Virol; 2011 Dec; 85(24):13253-9. PubMed ID: 21976653
[TBL] [Abstract][Full Text] [Related]
7. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
Kalnin K; Tibbitts T; Yan Y; Stegalkina S; Shen L; Costa V; Sabharwal R; Anderson SF; Day PM; Christensen N; Schiller JT; Jagu S; Roden RB; Almond J; Kleanthous H
Vaccine; 2014 Jun; 32(28):3540-7. PubMed ID: 24780250
[TBL] [Abstract][Full Text] [Related]
8. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types.
Zhang T; Chen X; Liu H; Bao Q; Wang Z; Liao G; Xu X
Vaccine; 2019 Jul; 37(30):4022-4030. PubMed ID: 31213378
[TBL] [Abstract][Full Text] [Related]
9. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.
Jiang RT; Wang JW; Peng S; Huang TC; Wang C; Cannella F; Chang YN; Viscidi RP; Best SRA; Hung CF; Roden RBS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28515303
[TBL] [Abstract][Full Text] [Related]
11. The full transcription map of mouse papillomavirus type 1 (MmuPV1) in mouse wart tissues.
Xue XY; Majerciak V; Uberoi A; Kim BH; Gotte D; Chen X; Cam M; Lambert PF; Zheng ZM
PLoS Pathog; 2017 Nov; 13(11):e1006715. PubMed ID: 29176795
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
[TBL] [Abstract][Full Text] [Related]
13. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
[TBL] [Abstract][Full Text] [Related]
14. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice.
Nardelli-Haefliger D; Roden R; Balmelli C; Potts A; Schiller J; De Grandi P
J Virol; 1999 Nov; 73(11):9609-13. PubMed ID: 10516071
[TBL] [Abstract][Full Text] [Related]
15. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
[TBL] [Abstract][Full Text] [Related]
17. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.
Cuburu N; Kweon MN; Hervouet C; Cha HR; Pang YY; Holmgren J; Stadler K; Schiller JT; Anjuère F; Czerkinsky C
J Immunol; 2009 Dec; 183(12):7851-9. PubMed ID: 19933861
[TBL] [Abstract][Full Text] [Related]
18. Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.
Sanders C; Matthews RL; Esfahani SHZ; Khan N; Patel NL; Kalen JD; Kirnbauer R; Roden RB; Difilippantonio S; Pinto LA; Shoemaker RH; Marshall JD
Vaccine; 2023 Jul; 41(31):4480-4487. PubMed ID: 37270364
[TBL] [Abstract][Full Text] [Related]
19. Protection Against H7 Subtype Influenza Virus Infection in Mice by Passive Transfer of Neutralizing Monoclonal Antibody.
Zhang Z; Liu M; Zheng S
Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):360-5. PubMed ID: 26492625
[TBL] [Abstract][Full Text] [Related]
20. Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice.
Yamanaka A; Pitaksajjakul P; Ramasoota P; Konishi E
Vaccine; 2015 Nov; 33(45):6070-7. PubMed ID: 26259543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
